Innovative Multivalent Nanobody Targeting ALB and IL-23 for Autoimmune Disease Intervention

VHH-P752 is a humanized nanobody currently in Biological Testing, designed to specifically target albumin (ALB) and the Interleukin 23 complex (IL-23). By combining specificity for both albumin and IL-23, VHH-P752 offers a dual action mechanism, presenting a novel therapeutic strategy for autoimmune disease. The optimized molecular design enhances biological stability and tissue distribution, which is particularly promising for the treatment of conditions where immune modulation is needed. This program represents a new generation of biotherapeutic agents with the potential to significantly improve outcomes for patients with autoimmune disease.

Licensing Opportunity

VHH-P752 is available for out-licensing and collaborative development opportunities. Partners interested in advancing innovative therapies for autoimmune disease are welcome to engage in discussions to explore mutual benefits.

Development Phase

Modality

VHH-P752 employs a multivalent nanobody format composed of two single variable domains that target IL-23, interconnected via flexible 9GS linkers and fused to a nanobody against serum albumin. The unique structural characteristics of nanobodies—including small molecular size, robust stability, and high solubility—support superior tissue penetration and sustained systemic presence. This modular design allows enhanced target engagement and pharmacokinetics, making VHH-P752 particularly advantageous for treating autoimmune diseases, where deep tissue access and lasting immunomodulation are often required. The multivalency further boosts binding affinity and selectivity, which may translate to improved therapeutic precision.

Target

ALB and IL-23 are both critical targets in the context of autoimmune disease. ALB, the most abundant plasma protein, is involved in maintaining oncotic pressure and transporting various endogenous and exogenous compounds within the bloodstream. IL-23 is a cytokine central to the differentiation and maintenance of Th17 cells, driving inflammatory responses and implicated in the pathogenesis of multiple autoimmune diseases. ALB is predominantly found in the liver and circulatory system, while IL-23 is mainly expressed by antigen-presenting cells such as macrophages and dendritic cells. Targeting ALB improves nanobody pharmacokinetics by leveraging its long plasma half-life, while focusing on IL-23 selectively modulates aberrant immune responses. VHH-P752’s dual targeting of ALB and IL-23 provides a strategic advantage by combining improved exposure with immunoregulatory efficacy—a highly attractive asset for next-generation autoimmune disease therapies.

Mechanism of Action

VHH-P752 exerts its effects through the simultaneous targeting of ALB and IL-23, acting as a signal transduction modulator in immune pathways. The anti-ALB component binds circulating albumin, prolonging systemic half-life and optimizing pharmacokinetic properties via albumin recycling. The anti-IL-23 moieties selectively bind and neutralize IL-23, disrupting pathogenic signal cascades that drive the differentiation of Th17 cells and subsequent autoimmune inflammation. This dual action not only extends therapeutic bioavailability but also directly regulates immune activity at key nodes. Furthermore, the flexible nanobody platform underlying VHH-P752 offers the potential for future therapeutic diversifications, such as antibody-drug conjugates (ADC) or engineered multispecific constructs, expanding possible applications in immune-mediated disorders.

Autoimmune Disease

Autoimmune diseases comprise a heterogeneous group of chronic disorders resulting from dysregulated immune responses against self-antigens, leading to tissue damage and functional impairment. These conditions—ranging from rheumatoid arthritis to psoriasis and inflammatory bowel disease—affect millions globally, representing a significant healthcare burden. The current mainstay treatments include immunosuppressive agents, corticosteroids, biologicals targeting specific cytokines or immune cells, and small molecule immunomodulators. However, many patients experience suboptimal efficacy, adverse effects, or progressive disease due to incomplete immune control or drug resistance. There is a pronounced unmet need for targeted immunotherapies with improved safety, pharmacokinetics, and tissue selectivity. By targeting ALB and IL-23, VHH-P752 offers a next-generation approach aiming for potent yet finely regulated immune modulation, which may address many limitations of existing therapies and improve patient outcomes across a broad spectrum of autoimmune conditions.